Designing effective strategies to combat HIV-1 requires structural knowledge of how antibodies (Abs) recognize HIV envelope proteins and how they are used by the immune system to eliminate viruses and virally-infected cells. Until recently, only a small number of broadly neutralizing antibodies (bNAbs) against HIV-1 had been characterized and the immunological basis for their breadth and potency remains poorly understood. The limited availability of bNAbs was resolved by new methods developed by Dr. Nussenzweig for HIV Ab isolation from the B cells of HIV-infected individuals. Several of these Abs, including NIH45-46, show superior potency and breadth to VRCOl, previously the best bNAb. We collaborated with Dr. Nussenzweig to solve the structure of NIH45-46 bound to gpl 20, and used structure-based design to increase its potency at least 10-fold, making NIH45-46 the best anti-HIV bNAb available as of its publication in 2011;we have now made an even more effective version (45-46m2) that neutralizes up to 97% of HIV strains. We will now collaborate with Drs. Nussenzweig to determine their mechanisms of action in animal models. The Ravetch laboratory has developed amino acid and glycan modifications of IgG Fc regions that optimize binding to activating Fc receptors, which will be introduced into designed bNAbs to increase their effector functions. In collaboration with Drs. Nussenzweig and Ravetch, we propose to determine the structural correlates of (i) broad/potent neutralization by the variable Fabs of bNAbs, and (ii) improved effector functions mediated by Fc regions. Information gleaned from these structures is directly relevant to """"""""reverse vaccination"""""""" involving gene therapy to deliver improved bNAbs and also required for immunogen design. This collaboration presents the opportunity to merge structural biology with in vitro and in vivo efficacy evaluations of new bNAbs against HIV, which will be facilitated by a set of scientific cores that will permit all three laboratories to quickly and accurately measure neutralization potencies and binding profiles of bNAbs (Core A, Automated Cell/Biochemical Assays Core), express large numbers of different bNAbs and HIV proteins (Core B, Protein Expression Core), and conduct experiments with HIV-infected humanized mice (Core C, Animal Services Core). The following specific aims will be pursued collaboratively: 1) Solve crystal structures of bNAb Fabs and bNAb Fab-gp120 complexes to define essential features of broad/potent HIV neutralization. 2) Solve crystal structures of IgG Fc regions and Fc/Fc receptor complexes to determine the structural effects of effector function-altering amino acid and glycan changes. 3) Produce natural antibody variants with enhanced activity in neutralization and mediating effector functions. 4) Use knowledge gained from these structural studies to design immunogens to elicit bNAbs.

Public Health Relevance

HIV/AIDS remains a critical threat to global public health. At least 60 million people have been infected with HIV. Although anti-retroviral drugs have been effective in the developed world, a vaccine and/or new methods to prevent infections are needed in the developing world. We will systematically analyze the structures of anti-HIV antibodies with the goal of understanding their protective mechanisms and routes of viral resistance, information that will be used to improve their efficacy and to design immunogens for vaccines.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
California Institute of Technology
United States
Zip Code
Scheid, Johannes F; Horwitz, Joshua A; Bar-On, Yotam et al. (2016) HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535:556-60
Lu, Ching-Lan; Murakowski, Dariusz K; Bournazos, Stylianos et al. (2016) Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352:1001-4
Escolano, Amelia; Steichen, Jon M; Dosenovic, Pia et al. (2016) Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell 166:1445-1458.e12
McGuire, Andrew T; Gray, Matthew D; Dosenovic, Pia et al. (2016) Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun 7:10618
Gautam, Rajeev; Nishimura, Yoshiaki; Pegu, Amarendra et al. (2016) A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533:105-9
Zolla-Pazner, Susan; Cohen, Sandra Sharpe; Boyd, David et al. (2016) Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. J Virol 90:636-49
Halper-Stromberg, Ariel; Nussenzweig, Michel C (2016) Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest 126:415-23
Steichen, Jon M; Kulp, Daniel W; Tokatlian, Talar et al. (2016) HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity 45:483-96
Gristick, Harry B; von Boehmer, Lotta; West Jr, Anthony P et al. (2016) Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat Struct Mol Biol 23:906-915
Scharf, Louise; West, Anthony P; Sievers, Stuart A et al. (2016) Structural basis for germline antibody recognition of HIV-1 immunogens. Elife 5:

Showing the most recent 10 out of 38 publications